Premium
Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies
Author(s) -
Piso Pompiliu,
Glockzin Gabriel,
von Breitenbuch Phillipp,
Popp Felix Cristoph,
Dahlke Marc Hendrik,
Schlitt Hans J.,
Nissan Aviram
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21327
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , cytoreductive surgery , quality of life (healthcare) , chemotherapy , life expectancy , surgery , intraperitoneal chemotherapy , cancer , ovarian cancer , population , nursing , environmental health
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with high morbidity. The Quality of Life (QoL) assessment in this patient group with a limited life expectancy and high recurrence rate is important. Published data show an impairment of postoperative Quality of Life at 3 months postoperatively with an improvement over 6–12 months at levels higher than the baseline. Standardized instruments QoL have to be included in clinical trials assessing the efficacy of CRS and HIPEC. J. Surg. Oncol. 2009;100:317–320. © 2009 Wiley‐Liss, Inc.